Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
RESEARCH TOOLSreports
KYTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $25.98
Previous CloseN/A
Volume87.17K
Average Volume (3M)300.41K
Market Cap
$102.75M
Enterprise Value-$101.36M
Total Cash (Recent Filing)$37.73M
Total Debt (Recent Filing)$10.56M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Apr 01, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding43,171,610
10 Day Avg. Volume313,429
30 Day Avg. Volume300,409
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit59.38
Enterprise Value/Ebitda0.93
Forecast
1Y Price Target
$40.00Price Target Upside1580.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Kyverna Therapeutics, Inc. News
PremiumCompany Announcements
Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth
PremiumCompany Announcements
Kyverna CMO Resignation Highlights Leadership Transition Impact---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company anticipates completing enrollment in the ongoing, potentially pivotal KYSA-8 study of KYV-101 in SPS with topline data expected, indicating progress in their clinical trials.
Financial StabilityCash on hand is expected to fund operations into 2027 with approximately $322 million as of September 30, 2024.
Safety And EfficacyThe company has observed no cases of severe cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome in over 50 patients dosed with KYV-101 to date.
Bears Say
Financial PerformanceKyverna reported a net loss of $0.80 per share in 3Q24, which is higher than the prior estimate of a net loss of $0.68 per share.
Leadership ChangesJames Chung, the company's CMO, will resign from his position to pursue other opportunities.
Research And Development CostsR&D and SG&A expenses were higher than expected, with $29.2M and $9.6M, respectively, compared to estimates of $27.5M and $6.2M.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.20 and its highest was $25.98 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $102.75M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Apr 01, 2025 which is in 8 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.014.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,171,610 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went down -5.138%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
---
Kyverna Therapeutics, Inc. Stock Smart Score
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
---
KYTX Stock 12 Month Forecast
Average Price Target
$40.00
▲(1580.67% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Allogene Therapeutics
―
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-64.88%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -64.88% per trade.
---